Search

everythinglearnresearchcommunity

for

Search:↓

The research confirms that Hidradenitis Suppurativa is characterized by increased inflammation, disrupted skin cell organization, and abnormal metabolic processes.

Melatonin helps grow more secondary hair follicles in young goats, improving cashmere production.

Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.

PCOS may increase the risk of mental health issues like depression and anxiety.

The document concludes that personalized hormonal treatments are important for transgender individuals and more research is needed for non-binary treatments.

Menopause can cause hair loss in women due to hormonal changes, affecting their well-being and quality of life.

Ion channels play a key role in ovarian cancer growth and treatment resistance.

Polycystic ovary syndrome increases the risk of diabetes, heart disease, and endometrial cancer, and requires early treatment to manage these risks.

LHX2 is crucial for development, tissue repair, and preventing diseases.

The 2023 guideline advises a detailed approach for PCOS, focusing on early detection, lifestyle and medical treatments, and managing health risks.

Oxidative stress worsens PCOS by damaging cells and disrupting metabolism, suggesting antioxidant treatments might help.

SARMs show promise but need more evidence to prove they're better than traditional androgens.

Hyaluronic Acid Profhilo® reduces skin inflammation and nerve-related pain in atopic dermatitis.

New methods may speed up drug development for male subfertility.

The roadmap calls for better research and funding to improve PCOS diagnosis, treatment, and health outcomes.

Chronic GnRHa treatment can help manage endometrial hyperplasia and reduce ovarian androgen excess in PCO patients.

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.

The nafarelin test can reliably distinguish between gonadotropin deficiency and delayed puberty in teenage boys.

The treatment successfully lowered testosterone levels and reduced symptoms.

The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.

The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.

GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.

A new model helps predict treatment success in girls with early puberty.

Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.

GnRH analogue can help diagnose ovarian causes of high testosterone in postmenopausal women when scans don't show the cause.